Merck, Healthy Interactions expand diabetes education program

Share this article:

Merck and Healthy Interactions announced an expansion of their US Diabetes Conversation Map Program, a patient education effort.

The program will launch in Spanish under the expansion, and will train 5,000 additional healthcare professionals, from 10,000 pre-existing participants, according to a company statement. Training and distribution are sponsored by Merck, whose diabetes drug, Januvia (sitagliptin), was approved in October 2006.  Janumet (sitagliptin/metformin), a combination pill, was approved in March 2007. Both products are indicated for Type 2 diabetes.

“Merck is firmly committed to improving patient education through our flagship program, Journey for Control, and we recognize the value and impact that this program has for patients with diabetes,” said Kathryn Hayward, US marketing leader, diabetes, at Merck in a statement.

Hispanics and Latinos are at a greater risk for Type 2 diabetes than non-Hispanics, according to US Department of Health and Human Services data included in the statement.

The Conversation Map Program exposes diabetes patients to a “lively, dynamic conversation where small groups of engaged participants are captivated by a thought provoking visual and real-world dialogue between patients and between patients and diabetes educators,” according to the statement.  A spokesperson at Merck was not immediately available for comment.

Share this article:

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...